CB Therapeutics
CB Therapeutics is a precision fermentation biotech that engineers yeast to biosynthetically produce rare compounds (cannabinoids, tryptamines, alkaloids, peptides) for pharmaceutical, biotech, and research customers. Operating from a 16,000 sq ft Carlsbad facility with eight US patents, it sells research-grade compounds and licenses platform IP.
- Company typePrivate
- Founded2018
- HeadquartersLa Jolla, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What CB Therapeutics does
CB Therapeutics is a precision fermentation biotech company founded in 2018 by Sher Butt (CEO) and Jacob Vogan (CSO), operating a 16,000 sq ft biomanufacturing facility in Carlsbad, California. The company engineers yeast strains to biosynthetically produce more than 100 rare compounds across eight classes, including phytocannabinoids, tryptamines, rare alkaloids, terpenes, peptides, and designed analogs, running an integrated platform from bioprospecting through strain engineering, fermentation, and downstream processing. The platform follows a closed-loop Design-Build-Test-Learn cycle underpinned by the proprietary TryptageniX AI data layer, and the company holds eight granted US patents spanning yeast strains, biosynthetic pathways, downstream chemistry, enzyme and gene mining, and bioinformatics methods.
The product surface is organized around four branded programs: TryptageniX (rare alkaloid research for mental-health therapeutics), TryptageniX AI (data and agentic-AI platform for biological design), Aevora (yeast-derived peptide extracts for healthspan, vitality, hair, skin, and metabolic health), and Korvane (non-opioid pain research featuring minor-kratom alkaloid blends with liposomal delivery). The company generates revenue through B2B sales of research-grade and pharmaceutical-grade compounds, research collaborations, and licensing of proprietary biosynthesis pathways. Customers are concentrated in pharma companies, biotech firms, and research institutions developing psychedelic-inspired, tryptamine-based, and pain therapeutics, with named engagements including Cleveland Clinic (2020 MOU for psilocybin, DMT, MDMA research samples) and an unnamed Colorado research client receiving the first research-supply delivery in June 2020. Distribution is exclusively through direct B2B partnership outreach with no self-serve or consumer channel.
CB Therapeutics firmographics
Firmographics- Name
- CB Therapeutics
- Legal name
- CB Therapeutics Inc.
- Website
- https://cbthera.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CB Therapeutics is a precision fermentation biotech that engineers yeast to biosynthetically produce rare compounds (cannabinoids, tryptamines, alkaloids, peptides) for pharmaceutical, biotech, and research customers. Operating from a 16,000 sq ft Carlsbad facility with eight US patents, it sells research-grade compounds and licenses platform IP.
- Ownership category
- akta.pro rank
CB Therapeutics industry classification
Industry- Product category
- Biopharmaceutical Manufacturing
- NAICS
- Medicinal and Botanical Manufacturing (325411), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Herbal & Botanical Supplements (CRADAGAD)
- akta.pro secondary industries
- Sleep, Stress & Mood Support (HLAIADAG), Controlled Substances / DEA-Scheduled API Manufacturing (HLAGAHAD)
Keywords
Where CB Therapeutics is headquartered
LocationHeadquarters
- HQ city
- La Jolla
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
CB Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain
Revenue model
- Biosynthetic Compound Sales: Sale of research-grade and pharmaceutical-grade compounds produced via precision fermentation. Compounds sold to research institutions, pharma companies, and wellness companies for mental health research, therapeutics development, and consumer product formulation.
- Research Collaborations & Licensing: Collaborative research arrangements with pharmaceutical partners, research institutions, and formulation companies. Includes licensing of proprietary biosynthesis pathways and co-development partnerships.
- Platform Technology Access: Partnership-based access to the fermentation platform for specific compound classes, enzyme engineering services, and strain development for external partners.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
CB Therapeutics product offering
Product offeringCore offering
CB Therapeutics operates a precision fermentation platform that uses engineered yeast strains to biosynthetically produce over 100 rare compounds across eight classes, including phytocannabinoids (CBD, CBG, CBC, CBN, THCV), tryptamines (psilocybin, DMT, baeocystin, 5-HTP), rare alkaloids (mitragynine, stemmadenine acetate, catharanthine, tabersonine, salvinorin A), terpenes, ergolines, peptides, and designed analogs. The company supplies research-grade and pharmaceutical-grade compounds to pharmaceutical, biotech, research, wellness, and food-tech customers through direct B2B partnerships, research collaborations, and licensing agreements, with four branded programs—TryptageniX, TryptageniX AI, Aevora, and Korvane—covering mental health, AI-guided biological design, healthspan peptides, and non-opioid pain research.
Product overview
CB Therapeutics operates a unified precision fermentation platform with four branded programs. The core platform uses engineered yeast strains to biosynthetically produce rare compounds across eight classes: phytocannabinoids, cannabinoid analogs, terpenes, tryptamines, tryptamine analogs, rare alkaloids, food-tech compounds, and novel food additives. Four programs build on this platform: TryptageniX (rare alkaloid research for mental health), TryptageniX AI (AI-guided data platform for agentic biological design), Aevora (peptide-enriched extracts for healthspan), and Korvane (minor keto alkaloid blend for non-opioid pain research). The platform has achieved 99.6% purity benchmarks and holds 8 granted US patents.
Differentiator
Problem solved
Functional benefit
Brands
- TryptageniX: Rare alkaloid research program covering MIA pathway, mitragynine, ergolines, and salvinorins for mental health applications.
- TryptageniX AI
- Aevora
- Korvane
Products and services
- Precision Fermentation Platform A yeast-based precision fermentation platform that biosynthetically produces over 100 rare compounds including phytocannabinoids, tryptamines, ergolines, alkaloids, peptides, and terpenes for pharmaceutical, biotech, research, wellness, and food-tech customers.
- TryptageniX A rare alkaloid research program developing fermentation routes for natural products limited by scarce source material. Covers MIA pathway intermediates (stemmadenine acetate, tabersonine, catharanthine), kratom alkaloids (mitragynine), ergolines (agroclavine), and salvinorins for mental health research and therapeutics.
- TryptageniX AI The data and AI platform behind CBT's fermentation platform that converts wet-lab cycles into training signal for agentic AI. Captures strain designs, fermentation outcomes, sample analysis, and structured data to sharpen biological design decisions.
- Aevora A peptide-enriched yeasted extract program for healthspan applications including vitality, hair and skin health, metabolic rhythm, and body composition. Produced through precision fermentation in yeast without animal-source material.
- Korvane A non-opioid pain research program featuring a precision blend of minor kratom alkaloids (paynantheine, speciociliatine, and proprietary lead alkaloid) produced via yeast fermentation and formulated for liposomal delivery. Targets chronic pain without the dominant alkaloids carrying opioid-like risk.
Quantifiable outcome
- 99.6% purity achieved on rare cannabinoids (CBC benchmark, 2021)
- +2 more outcomes
Companies that use CB Therapeutics
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles5 records
CB Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature5 records
CB Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Cleveland CliniccoreMOU signed to provide research-use samples of psilocybin, DMT, and MDMA to Cleveland Clinic for depression, addiction, and PTSD studies. Validates platform's ability to produce clinical-grade compounds for medical research.
Scale indicators7 records
Recent moves8 records
Expansion highlights6 records
CB Therapeutics competitors and assessment
Company assessmentDirect peers
- Ginkgo Bioworks: Largest publicly listed precision fermentation / cell engineering platform; offers strain engineering, fermentation, and downstream services across many of the same end-markets (food ingredients, flavors, cannabinoids, therapeutics). Directly comparable as a multi-vertical fermentation platform with code-driven strain design.
- Amyris: Fermentation-derived specialty ingredients company that produced cannabinoids (e.g., CBG), terpenes, and flavor/fragrance molecules from engineered yeast at commercial scale. Closely comparable business model of using precision fermentation to serve wellness, flavor, and consumer product markets.
- Conagen: Precision fermentation company producing rare and sustainable ingredients via engineered microbes, including cannabinoids, flavors, fragrances, and nutritional compounds. Closely comparable in scale, technology stack, and target customer segments.
- Checkerspot: Biotech using precision fermentation to produce novel oils, polyols, and ingredients for personal care, food, and materials. Comparable as a fermentation platform commercializing novel compounds via B2B partnerships with consumer-facing brands.
- Lumen Bioscience: Clinical-stage biotech using engineered spirulina/yeast-based precision fermentation to manufacture biologics, peptides, and therapeutic proteins at scale. Comparable in combining fermentation manufacturing with pharma-style therapeutic development for rare compounds.
- Pivot Bio: Precision fermentation company producing microbial nitrogen-fixing and crop nutrition products for agriculture. Comparable as a venture-backed fermentation platform company that has successfully commercialized engineered-microbe products in a regulated B2B market.
- Ingenza: Industrial biotechnology / contract research organization offering precision fermentation, strain engineering, and bioprocess development services to pharma and specialty chemical clients. Comparable as a service-and-platform provider of microbial production for rare and high-value compounds.
Broad incumbents
- Codexis: Public enzyme-engineering and biocatalysis company serving pharmaceutical, food, and industrial customers. Overlapping in enzyme and pathway engineering IP for small-molecule and biological manufacturing, though Codexis is more established and broader in scope.
Emerging players
- Compass Pathways: Clinical-stage mental health company developing psilocybin therapy for treatment-resistant depression. Comparable end-market focus on psychedelic-derived mental-health therapeutics; differs in using chemical synthesis rather than biosynthesis for its COMP360 psilocybin.
Others
- ATAI Life Sciences: Clinical-stage biopharma platform developing psychedelic and mental-health therapeutics. Listed in CBT's materials as a joint venture partner on TryptageniX (ATAI relationship) and represents both a comparable psychedelic therapeutics peer and a financial/strategic partner.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
CB Therapeutics social profiles
Digital presenceCB Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
CB Therapeutics leadership team
Management profileNumber of profiles
Profiles14 records
CB Therapeutics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CB Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CB Therapeutics
What does CB Therapeutics do?
CB Therapeutics operates a precision fermentation platform that uses engineered yeast strains to biosynthetically produce over 100 rare compounds across eight classes, including phytocannabinoids (CBD, CBG, CBC, CBN, THCV), tryptamines (psilocybin, DMT, baeocystin, 5-HTP), rare alkaloids (mitragynine, stemmadenine acetate, catharanthine, tabersonine, salvinorin A), terpenes, ergolines, peptides, and designed analogs. The company supplies research-grade and pharmaceutical-grade compounds to pharmaceutical, biotech, research, wellness, and food-tech customers through direct B2B partnerships, research collaborations, and licensing agreements, with four branded programs—TryptageniX, TryptageniX AI, Aevora, and Korvane—covering mental health, AI-guided biological design, healthspan peptides, and non-opioid pain research.
Is CB Therapeutics a public or private company?
CB Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was CB Therapeutics founded?
CB Therapeutics was founded in 2018. It employs 11 to 50 people.
Where is CB Therapeutics based?
CB Therapeutics is headquartered in La Jolla, United States, in the North America region.
How does CB Therapeutics make money?
Three revenue lines are on record. Biosynthetic Compound Sales are the primary driver. The others are research Collaborations & Licensing and platform Technology Access.
Who are CB Therapeutics's main competitors?
Direct peers on record are Ginkgo Bioworks, Amyris, Conagen, Checkerspot, Lumen Bioscience, Pivot Bio and Ingenza. Codexis is listed as a broad incumbent. Compass Pathways is listed as an emerging player. ATAI Life Sciences is listed as an others.
Does CB Therapeutics have an API?
No public API is recorded for CB Therapeutics.
What industry is CB Therapeutics in?
CB Therapeutics's product category is Biopharmaceutical Manufacturing. Its primary akta.pro industry code is CRADAGAD, Herbal & Botanical Supplements, with a secondary code of HLAIADAG, Sleep, Stress & Mood Support. Its NAICS code is 325411 and its SIC code is 2833.